
    
      This research study is a Food and Drug Administration (FDA) mandated post market surveillance
      study of the Wingspan® Stent System, also known as the WEAVE™ Trial. The purpose of this
      trial is to fulfill a FDA requirement to evaluate the rate of stroke and/or death within 72
      hours of the procedure, in patients who have a Wingspan Stent implanted in accordance with
      the Indications for Use.
    
  